Keros Therapeutics (KROS) Return on Capital Employed (2020 - 2025)
Keros Therapeutics filings provide 6 years of Return on Capital Employed readings, the most recent being 12.99% for Q4 2025.
- On a quarterly basis, Return on Capital Employed rose 4997.0% to 12.99% in Q4 2025 year-over-year; TTM through Dec 2025 was 12.99%, a 4997.0% increase, with the full-year FY2025 number at 14.8%, up 6009.0% from a year prior.
- Return on Capital Employed hit 12.99% in Q4 2025 for Keros Therapeutics, up from 6.0% in the prior quarter.
- In the past five years, Return on Capital Employed ranged from a high of 12.99% in Q4 2025 to a low of 52.49% in Q4 2023.
- Median Return on Capital Employed over the past 5 years was 37.04% (2022), compared with a mean of 28.5%.
- Biggest five-year swings in Return on Capital Employed: crashed -1920bps in 2022 and later skyrocketed 4997bps in 2025.
- Keros Therapeutics' Return on Capital Employed stood at 24.43% in 2021, then plummeted by -79bps to 43.63% in 2022, then decreased by -20bps to 52.49% in 2023, then rose by 30bps to 36.98% in 2024, then surged by 135bps to 12.99% in 2025.
- The last three reported values for Return on Capital Employed were 12.99% (Q4 2025), 6.0% (Q3 2025), and 0.04% (Q2 2025) per Business Quant data.